深圳翰宇药业股份有限公司 审计报告及财务报表 二〇二四年度 信会师报字[2025]第 ZI10348 号 深圳翰宇药业股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-7 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-113 | 三、 事务所及注册会计师执业资质证明 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公允反映了翰宇药业 2024 年 12 月 31 日的合并及母公司 财务状况以及 2024 年度的合并及母公司经营成果和现金流量。 二、 形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计 报告的"注册会计师对财务报表审计的责任"部分进一步阐述 ...

关于深圳翰宇药业股份有限公司 二〇二四年度 营业收入扣除情况表的鉴证报告 信会师报字[2025]第ZI10351号 关于深圳翰宇药业股份有限公司2024年度 营业收入扣除情况表的鉴证报告 信会师报字[2025]第ZI10351号 深圳翰宇药业股份有限公司全体股东： 我们审计了深圳翰宇药业股份有限公司(以下简称"翰宇药业公 司")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流量 表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 24 日出具了报告号为信会师报字[2025]第 ZI10348 号的无保 留意见审计报告。 在对上述财务报表执行审计的基础上，我们接受委托，对后附的 翰宇药业公司2024年度营业收入扣除情况表（以下简称"营业收入扣 除情况表"）执行了合理保证的鉴证业务。 一、 管理层的责任 翰宇药业公司管理层的责任是按照《深圳证券交易所创业板股票 上市规则》和《深圳证券交易所创业板上市公司自律监管指南第1号— —业务办理》的相关规定编制营业收入扣除情况表，确保营业收入扣 除情况 ...

深圳翰宇药业股份有限公司 二〇二四年度 内部控制审计报告 信会师报字[2025]第 ZI10349 号 内部控制审计报告 信会师报字[2025]第 ZI10349 号 深圳翰宇药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了深圳翰宇药业股份有限公司（以下简称"翰宇药 业"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是翰宇药业董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 第 1 页 中国注册会计师： 中国·上海 2025 年 ...

国浩律师（深圳）事务所 关于 深圳翰宇药业股份有限公司 二〇二二年限制性股票激励计划 作废限制性股票相关事项 的 法律意见书 北京·上海·深圳·杭州·广州·昆明·天津·成都·宁波·福州·西安·南京·南宁·济南·重庆 Beijing·Shanghai·Shenzhen·Hangzhou·Guangzhou·Kunming·Tianjin·Chengdu ·Ningbo ·Fuzhou·Xi`an·Nanjing·Nanning·Jinan·Chongqing 苏州·长沙·太原·武汉·贵阳·乌鲁木齐·郑州·石家庄·合肥·海南·青岛·南昌·大连·银川·拉孜 Suzhou·Changsha·Taiyuan·Wuhan ·Guiyang·Wulumuqi·Zhengzhou·Shijiazhuang·Hefei·Hainan·Qingdao·Nanchang·Dalian·Yinchuan·Lhatse 香港·巴黎·马德里·硅谷·斯德哥尔摩·纽约·马来西亚·柬埔寨 Hongkong·Paris·Madrid·Silicon Valley·Stockholm·New York·Malaysia·Cambodia 深圳市深 ...

翰宇药业（300199）公告，2025年第一季度营业收入3.1亿元，同比增长106.29%。净利润6986.84万 元，同比增长595.45%。 ...

Revenue and Profitability - The company's revenue for Q1 2025 reached ¥309,969,965.34, representing a 106.29% increase compared to ¥150,256,744.79 in the same period last year[5] - Net profit attributable to shareholders was ¥69,868,367.53, a significant turnaround from a loss of ¥14,102,003.37, marking a 595.45% increase[5] - Basic and diluted earnings per share improved to ¥0.08, compared to a loss of ¥0.02 per share in the same period last year, reflecting a 500.00% increase[5] - The net profit for the current period was ¥69,439,025.34, a turnaround from a net loss of ¥14,350,051.02 in the previous period[22] - The profit attributable to the parent company's shareholders was ¥69,868,367.53, compared to a loss of ¥14,102,003.37 in the prior period[23] - The company reported a total comprehensive income of ¥69,339,641.98, recovering from a loss of ¥14,111,841.40 in the previous period[23] Cash Flow - The net cash flow from operating activities was ¥40,425,295.32, up 166.79% from ¥15,152,592.91 in the previous year[5] - Cash flow from operating activities showed a significant improvement, with cash received from sales reaching ¥190,318,882.35, compared to ¥130,536,094.26 in the previous period[25] - The net cash flow from operating activities was $40,425,295.32, an increase from $15,152,592.91 in the previous period, indicating a significant improvement in operational efficiency[26] - Total cash inflow from financing activities was $70,000,000.00, while cash outflow amounted to $120,077,959.58, resulting in a net cash flow of -$50,077,959.58, reflecting a decrease in financing activities[26] - The total cash inflow from investment activities was $3,746,209.90, while cash outflow was $34,282,205.58, leading to a net cash flow of -$30,535,995.68, indicating a substantial investment in assets[26] - The company received $9,311,755.88 in tax refunds, contributing positively to cash inflows from operating activities[26] Assets and Liabilities - The total assets at the end of Q1 2025 were ¥3,038,045,570.70, a slight increase of 0.99% from ¥3,008,225,640.09 at the end of the previous year[5] - Total current assets amount to ¥494,618,808.48, an increase from ¥463,048,006.84 at the beginning of the period[18] - Total liabilities decreased slightly to ¥2,371,659,416.70 from ¥2,411,179,128.07, reflecting a reduction of approximately 1.6%[22] - The company has a total of ¥82,878,785.91 in contract liabilities, down from ¥124,478,071.04, indicating a reduction of approximately 33%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 57,273[14] - The largest shareholder, Zeng Shaogui, holds 11.16% of shares, amounting to 98,533,635 shares, with 95,732,245 shares pledged[14] - The company is actively involved in financing activities, with a notable shareholder, Tibet Rongrui Investment Co., holding 5,286,600 shares through margin trading[15] Operating Costs and Expenses - The company's operating costs increased by 115.64% to ¥128,088,503.11, mainly due to higher formulation costs[10] - Total operating costs amounted to ¥231,507,233.07, compared to ¥156,147,173.76 in the prior period, indicating an increase of about 48.2%[22] - Cash paid to employees increased to ¥58,222,746.22 from ¥35,535,450.97, reflecting a rise in labor costs[26] Research and Development - The company has ongoing research and development efforts, with development expenditures amounting to ¥142,685,817.52, up from ¥136,673,090.93[18] - Research and development expenses rose to ¥21,707,434.32 from ¥18,999,351.04, an increase of approximately 9.0%[22] Inventory and Accounts Receivable - The increase in accounts receivable was 73.91%, reaching ¥166,562,869.28, primarily due to increased revenue[9] - Accounts receivable increased significantly to ¥166,562,869.28 from ¥95,773,533.23, indicating a growth of approximately 74%[18] - Inventory decreased to ¥225,749,209.48 from ¥238,630,347.88, reflecting a decline of about 5.4%[18] Audit and Reliability - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[28]

Financial Performance - The net profit attributable to shareholders of the company significantly reduced losses year-on-year, primarily due to changes in revenue structure and an increase in overseas revenue proportion[7]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 25% year-over-year growth[21]. - The company's operating revenue for 2024 reached ¥590,199,011.64, representing a 36.82% increase compared to ¥431,384,112.87 in 2023[26]. - The net profit attributable to shareholders improved to -¥173,654,017.08 in 2024, a 66.21% reduction in losses from -¥513,876,149.69 in 2023[26]. - The net cash flow from operating activities surged to ¥164,705,660.55, a significant increase of 4,757.21% compared to -¥3,536,573.51 in 2023[26]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was -¥239,652,787.96 in 2024, a 59.44% improvement from -¥590,913,670.38 in 2023[26]. - The basic and diluted earnings per share improved to -¥0.20 in 2024, a 65.52% increase from -¥0.58 in 2023[26]. - The company's weighted average return on equity improved to -26.02% in 2024, up 24.62% from -50.64% in 2023[26]. Revenue Growth and Market Expansion - The overseas sales of peptide formulations and active pharmaceutical ingredients continued to grow, driving overall revenue growth for the company[7]. - The report indicates a substantial increase in overseas business, contributing to the overall revenue growth[7]. - The company is expanding its market presence in Europe, targeting a 20% increase in market share by the end of the fiscal year[21]. - The international business accounted for over 50% of total revenue, with overseas sales of liraglutide formulations and GLP-1 raw materials significantly contributing to growth, achieving a 189.79% increase in foreign revenue[76][78]. - The company plans to accelerate its global strategy in peptide and small nucleic acid formulations, as well as API and CDMO/CMO businesses, targeting markets in North America, South America, Europe, Asia, and the Middle East[38]. Research and Development - New product development includes a novel nasal spray for COVID-19, developed in collaboration with the Chinese Academy of Sciences[20]. - Clinical trials for the new GLP-1 receptor agonist are progressing, with Phase III trials expected to start in Q2 2024[20]. - The company aims to enhance its R&D efficiency and product competitiveness by integrating cutting-edge technologies such as biotechnology and artificial intelligence into its processes[38]. - The company is focused on expanding its research and development capabilities, particularly in peptide drug development, with over 15 years of experience in the field[159]. - The company is advancing multiple products towards market approval, including HY3000 and HY3001, which are in clinical trials aimed at obtaining Chinese market licenses[96]. Operational Efficiency and Cost Management - The company aims to reduce operational costs by 10% through improved supply chain management strategies[21]. - The company is investing 100 million RMB in new technology for drug manufacturing to improve efficiency and reduce costs[21]. - The management team has implemented refined operational processes across the supply chain, enhancing efficiency and service quality[58]. - The company has established a comprehensive quality management system, achieving certifications from multiple international regulatory bodies, including FDA and GMP[57]. Corporate Governance and Compliance - The company emphasizes strict quality control throughout the drug production process to mitigate risks related to product quality[129]. - The company has established a value management system to enhance transparency and align market value with intrinsic value[133]. - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring compliance with relevant laws and regulations[143]. - The company strictly adheres to legal requirements for information disclosure, ensuring timely and accurate communication with shareholders through designated media[144]. - The company maintains a clear separation of assets, personnel, finance, institutions, and business from its controlling shareholder, ensuring independent operations[148]. Shareholder Engagement and Social Responsibility - The company has committed to social responsibility initiatives, including poverty alleviation and ecological protection, while ensuring shareholder interests[146]. - The company ensures equal treatment of all shareholders, particularly minority shareholders, allowing them to fully exercise their rights[138]. - The company actively communicates with investors through various channels, enhancing understanding and recognition among stakeholders[145]. Future Outlook and Strategic Goals - Future development strategies and plans are outlined in the management discussion and analysis section, emphasizing the need for investors to recognize associated risks[7]. - The company anticipates 2025 to be a pivotal year for growth, driven by optimized product structure and improved operational efficiency[124]. - The company plans to enhance its international strategy by expanding overseas marketing, accelerating product registration, and strengthening global partnerships[122]. - The company is committed to addressing potential risks in drug innovation and development, ensuring a robust pipeline of products[126]. Internal Control and Risk Management - The company has established a strict internal control system to manage risks and ensure compliance, enhancing the internal audit function[190]. - The company has not reported any significant internal control deficiencies during the reporting period[191]. - The supervisory board found no significant risks during its oversight activities in the reporting period[179]. - Measures are in place to prevent core technology leakage, including confidentiality agreements and enhanced information security systems[128].

二、董事会专门委员会履职情况 深圳翰宇药业股份有限公司 2024年度独立董事述职报告 （钟廉） 本人作为深圳翰宇药业股份有限公司（以下简称"公司"）的独立董事，在 2024年任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《关于在上市公司建立独立董事制度的指导意见》《深圳翰宇药业股份有限公司 公司章程》（以下简称"《公司章程》"）《深圳翰宇药业股份有限公司独立董事 工作制度》等相关法律、法规、规章的规定和要求，做到诚实、勤勉、独立的履 行职责，积极出席相关会议，认真审议董事会各项议案，对公司重大事项发表了 独立意见，较好地发挥了独立董事及专业委员的作用。现就本人2024年度履行独 立董事职责情况述职如下： 一、出席会议情况 本着勤勉尽责的态度，我积极参加公司召开的董事会和股东大会。报告期内， 共参与了9次董事会会议，未出现连续两次未亲自出席会议的情形。在审议董事 会各项议案过程中，我坚持独立、审慎的判断原则，结合自身专业知识和对公司 实际情况的了解，认真履行表决权。在审议过程中对相关议案提出了意见和建议， 并根据具体情况发表了相应独立意见。在我看来，报告期内公司董事会和股东大 会的召集和召开 ...

深圳翰宇药业股份有限公司 关联交易管理制度 第一章 总则 第一条 为规范深圳翰宇药业股份有限公司（以下简称"公司"或"本公司"） 关联交易的决策管理和信息披露等事项，确保公司的关联交易行为不损害公司和全 体股东特别是无关联关系股东的利益，根据《中华人民共和国公司法》、《中华人 民共和国证券法》、《企业会计准则》、《深圳证券交易所创业板股票上市规则》 （以下简称"《创业板股票上市规则》"）及其他有关法律法规、规范性文件和《公 司章程》的规定，结合公司实际情况，特制定本制度。 （一）直接或间接地控制公司的法人或其他组织； 第二条 公司关联交易的决策管理、信息披露等事项，应当遵守本制度。 第三条 公司处理关联交易事项，应当遵循下列原则： （一）诚实信用的原则； （二）公开、公平、公正的原则； （三）依据客观标准判断的原则； （四）实质重于形式的原则。 第二章 关联人和关联关系 第四条 公司关联人包括关联法人和关联自然人。 第五条 具有下列情形之一的法人或其他组织，为本公司的关联法人： （二）由前项所述法人直接或间接控制的除本公司及其控股子公司以外的法人 或其他组织； （三）由第六条所列本公司的关联自然人直接或间接控 ...

深圳翰宇药业股份有限公司 2024年度独立董事述职报告 （许立勇） 本人作为深圳翰宇药业股份有限公司（以下简称"公司"）的独立董事，在2024 年任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》《关 于在上市公司建立独立董事制度的指导意见》《深圳翰宇药业股份有限公司公司 章程》（以下简称"《公司章程》"）《深圳翰宇药业股份有限公司独立董事工作 制度》等相关法律、法规、规章的规定和要求，做到诚实、勤勉、独立的履行职 责，积极出席相关会议，认真审议董事会各项议案，对公司重大事项发表了独立 意见，较好地发挥了独立董事及专业委员的作用。现就本人2024年度履行独立董 事职责情况述职如下： 一、出席会议情况 本人于 2024 年度新任公司独立董事，因任职时间尚短，自受聘至 2024 年 12 月 31 日期间，公司尚未召开董事会会议或相关专门委员会会议，因此本人在 该期间未参与相关议案的审议表决。 尽管如此，任职以来本人始终高度重视独立董事职责，始终秉持勤勉尽责、 独立公正的原则，积极主动履职。在任期内，我多次到访公司，深入了解企业运 作实际情况，主动与公司董事会成员及管理层开展深入沟通，就公司经营状况 ...